Table 2. BAL samples obtained and analyzed in the enrolled patients.
| Active TB | LTBI | No LTBI | ||||||||||
| Samples not available for the analysis | Total samples analyzed | Samples not available for the analysis | Total samples analyzed | Samples not available for the analysis | Total samples analyzed | |||||||
| Cell constraint | Cell anergy | Indeterminate | Cell constraint | Cell anergy | Indeterminate | Cell constraint | Cell anergy | Indeterminate | ||||
| ELISPOT: N/total (%) | - | 1/20 (5) | 3/20 (15) | 16/20 (80) | - | 1/9 (11) | 1/9 (11) | 7/9 (78) | - | - | 3/12 (25) | 9/12 (75) |
| FACS: N/total (%) | 6/20 (30) | - | - | 14/20 (70) | 4/9 (44) | - | - | 5/9 (56) | 3/12 (25) | - | - | 9/12 (75) |
Footnote: ELISPOT: enzyme-linked immunosorbent spot; FACS: flow cytometric analysis; TB: tuberculosis; LTBI: latent tuberculosis infection; cell constraint: mononuclear cells from BAL < 6×106; cell anergy: by ELISPOT, if the results are less than 20 SFC/well in the positive control; cell anergy: by FACS, if the results are less than 0.06% in the positive control; indeterminate: by ELISPOT, if the results are more than 10 SFC/well in the negative control.